iXensor
Market Cap
NT$1.1b
Last Updated
2021/06/18 08:39 UTC
Data Sources
Company Financials
Executive Summary
iXensor Co., Ltd. develops, produces, and sells hardware and software systems for in-vitro diagnostic medical devices. More Details
Rewards
Risk Analysis
+ 1 more risk
Snowflake Analysis
Adequate balance sheet with weak fundamentals.
Share Price & News
How has iXensor's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6734 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: 6734's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of TW stocks.
Market Performance
7 Day Return
-4.4%
6734
2.8%
TW Medical Equipment
1.3%
TW Market
1 Year Return
6.8%
6734
-5.1%
TW Medical Equipment
48.5%
TW Market
Return vs Industry: 6734 exceeded the TW Medical Equipment industry which returned -5.9% over the past year.
Return vs Market: 6734 underperformed the TW Market which returned 48.1% over the past year.
Shareholder returns
| 6734 | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.4% | 2.8% | 1.3% |
| 30 Day | -1.6% | 12.6% | 8.1% |
| 90 Day | 28.7% | 13.9% | 8.0% |
| 1 Year | 6.8%6.8% | -2.9%-5.1% | 53.3%48.5% |
| 3 Year | n/a | 16.3%6.6% | 75.9%55.7% |
| 5 Year | n/a | 8.6%-5.6% | 140.8%97.9% |
Long-Term Price Volatility Vs. Market
How volatile is iXensor's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Will iXensor (GTSM:6734) Spend Its Cash Wisely?Valuation
Is iXensor undervalued compared to its fair value and its price relative to the market?
13.71x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6734's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 6734's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 6734 is unprofitable, so we can't compare its PE Ratio to the TW Medical Equipment industry average.
PE vs Market: 6734 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6734's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6734 is overvalued based on its PB Ratio (13.7x) compared to the TW Medical Equipment industry average (2.1x).
Future Growth
How is iXensor forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
18.9%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iXensor has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has iXensor performed over the past 5 years?
3.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6734 is currently unprofitable.
Growing Profit Margin: 6734 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6734 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare 6734's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6734 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.9%).
Return on Equity
High ROE: 6734 has a negative Return on Equity (-96.87%), as it is currently unprofitable.
Financial Health
How is iXensor's financial position?
Financial Position Analysis
Short Term Liabilities: 6734's short term assets (NT$69.1M) exceed its short term liabilities (NT$16.8M).
Long Term Liabilities: 6734's short term assets (NT$69.1M) exceed its long term liabilities (NT$1.6M).
Debt to Equity History and Analysis
Debt Level: 6734 is debt free.
Reducing Debt: 6734 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6734 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 6734 has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.4% each year.
Dividend
What is iXensor current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6734's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6734's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6734's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6734's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6734's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
iXensor has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.4%.
Top Shareholders
Company Information
iXensor Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: iXensor Co., Ltd.
- Ticker: 6734
- Exchange: TPEX
- Founded: 2012
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: NT$1.149b
- Shares outstanding: 52.35m
- Website: https://www.ixensor.com
Location
- iXensor Co., Ltd.
- No.9, Aly. 2, Ln. 35
- 6th Floor
- Taipei
- 11492
- Taiwan
Listings
Biography
iXensor Co., Ltd. develops, produces, and sells hardware and software systems for in-vitro diagnostic medical devices. The company’s PixoTest technology uses the lighting and image sensing module of the sm...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/06/18 08:39 |
| End of Day Share Price | 2021/06/17 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.